Hand holding smartphone with Superluminal logo against red tech-themed background.

INSIGHTS

14 Aug 2025

The Next Obesity Breakthrough Could Be Written in Code

Eli Lilly partners with Superluminal to tap Al for faster obesity drug discovery beyond injectables.

Brown pill bottles labeled Aleniglipron with white tablets on a gray surface.

INVESTMENT

7 Aug 2025

Structure Extends Runway to 2027 Ahead of Key 2025 Data

Structure raised $300M to advance its oral GLP-1 pill, with key data due in 2025 and cash runway into 2027.

Eli Lilly sign in front of modern corporate building on a sunny day.

PARTNERSHIPS

26 Jul 2025

One Shot for Cholesterol? Lilly Thinks the Future Is Here

Lilly's Verve buyout could turn lifelong cholesterol drugs into a one-time genetic fix.

Gloved hand uses tweezers to edit a DNA strand against a blue background.

INNOVATION

28 Jun 2025

CRISPR’s Bold Bet: One Shot to Disrupt Cholesterol Care

CTX310 shows up to 86% LDL reduction in early trial, with full results expected in 2025

Close-up of a Novo-branded white pill on a reflective dark surface.

INNOVATION

25 Jun 2025

From Needle to Pill: The New Face of Obesity Treatment

Novo's amycretin pill shows big early weight-loss results, hinting at a future beyond injections.

Signboard showing Vertex logo beside Alexandria 3215 marker in landscaped outdoor setting.

RESEARCH

21 Jun 2025

Stem Cell Trial Offers Hope for Insulin-Free Diabetes

Vertex's zimislecel left most trial patients insulin-free after a year, but safety risks and scalability remain major hurdles

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.